Diabetes mellitus
Conditions
Interventions
Seventy-five patients with insulin-dependent diabetes mellitus (type 1 or LADA) that are screened regularly for the Association of Diabetics of Ourinhos (ADO) were selected. Of these patients: 25 use
25 use simple multiple daily injections (MDI)
the other 25 patients use insulin in MDI under carbohydrate counts.
All 75 patients will be submitted, at the initial and final moments of the study, to: collection of glycated hemoglobin (A1C) and ap
Device
Sponsors
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Associação dos Diabéticos de Ourinhos (ADO)
Eligibility
Age
0 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients under following at ADO with type 1 DM or LADA. Any age. Any A1C. Use of insulin analogues (ultra-slow - Detemir, Glargina 100, Glargina 300, Degludeca - and ultrafast - Glulisine, Aspart or Lispro). In the subgroup of patients under carbohydrate counts, those who have had this modality of treatment for at least 3 (three) months. In the subgroup of patients undergoing treatment with CSII, those who have had this treatment modality for at least 3 (three) months.
Exclusion criteria
Exclusion criteria: Patients with other types of DM than those previously mentioned. Patients who use insulin, but not in MDI scheme. Patients treated with conventional insulin (NPH - Neutral Protamine Hagedorn - and regular), although in an MDI scheme.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For this study, the improvement of adherence to treatment was equated with the optimization of glycemic control, which was objectively defined as the combined meeting of ALL the following criteria: Perform at least 4 (four) daily measures of capillary glycemia in more than 50% of the days of the weeks-focus. Report sports practice to the OneTouch Reveal® application, when done. For patients in the CSII group, perform temporary baselines when exercising. Reduced mean glycemia after meals between the initial and intermediate weeks (4 th and 8 th weeks of the study) or between the initial and final weeks of the study (weeks 4 and 12 of the study). Reduction of the total percentage of hyperglycaemia (capillary glycemia measurements greater than 180mg / dL or 10mmol / L) between the initial and intermediate focus weeks (4a and 8a weeks of the study) or between the initial and final focus weeks (4a and 12 weeks of study). | — |
Secondary
| Measure | Time frame |
|---|---|
| It was considered as secondary outcome of this study the combined encounter between: Absolute reduction between A1C start and end values. Increase in DSMP total score between your initial and final applications. | — |
Countries
Brazil
Contacts
Public ContactFelipe de Oliveira
Associação dos Diabéticos de Ourinhos (ADO)
Outcome results
None listed